Published in J Virol on April 01, 1992
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol (1994) 6.60
Visualization of the intracellular behavior of HIV in living cells. J Cell Biol (2002) 6.59
Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J (1992) 6.05
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol (1994) 4.65
Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol (2003) 4.47
Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J (1998) 4.46
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (1999) 4.46
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1994) 4.28
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol (1995) 4.19
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A (2003) 4.03
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 3.95
Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol (2004) 3.54
Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med (1998) 3.22
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A (1996) 3.07
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol (1996) 2.86
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol (1998) 2.82
Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol (1998) 2.79
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol (2004) 2.65
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
Fusion from without directed by human immunodeficiency virus particles. J Virol (1994) 2.62
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J Virol (1995) 2.59
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A (1994) 2.59
Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog (2010) 2.57
A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A (1997) 2.52
High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol (1998) 2.47
Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol (2002) 2.43
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol (1996) 2.39
Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol (2006) 2.32
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol (2000) 2.27
Macrophages archive HIV-1 virions for dissemination in trans. EMBO J (2005) 2.27
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23
Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J Virol (1994) 2.21
Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay. J Virol (1993) 2.18
Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol (1995) 2.17
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol (1999) 2.15
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol (1999) 2.12
Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol (1995) 2.08
Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol (1996) 2.07
Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol (2004) 2.06
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol (2005) 2.05
Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol (2005) 2.05
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol (1998) 2.03
Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol (1999) 2.02
The cell cycle independence of HIV infections is not determined by known karyophilic viral elements. PLoS Pathog (2005) 2.02
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol (2005) 2.02
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A (2007) 2.02
Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci U S A (1996) 2.01
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J Virol (1998) 1.97
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother (2001) 1.96
Early steps of retrovirus replicative cycle. Retrovirology (2004) 1.94
Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol (2002) 1.91
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol (2004) 1.91
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol (2004) 1.90
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. EMBO J (1998) 1.86
Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc Natl Acad Sci U S A (2007) 1.85
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol (2008) 1.84
Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol (1999) 1.81
RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol (2002) 1.80
Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol (2012) 1.77
The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4. J Virol (1993) 1.74
Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J Virol (1998) 1.72
Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol (1993) 1.71
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother (2008) 1.68
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol (2001) 1.66
Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol (2001) 1.65
Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol (2001) 1.63
Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A (2006) 1.63
Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission. J Virol (1999) 1.61
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
A short amino acid sequence able to specify nuclear location. Cell (1984) 21.17
Improved retroviral vectors for gene transfer and expression. Biotechniques (1989) 19.48
Nucleotide sequence of the AIDS virus, LAV. Cell (1985) 16.81
Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A (1985) 8.53
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
The accuracy of reverse transcriptase from HIV-1. Science (1988) 8.24
Fidelity of HIV-1 reverse transcriptase. Science (1988) 8.08
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16
The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell (1989) 6.13
Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology (1991) 5.54
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
Receptor interference groups of 20 retroviruses plating on human cells. Virology (1990) 4.15
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol (1991) 3.71
Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol (1990) 3.14
New retrovirus helper cells with almost no nucleotide sequence homology to retrovirus vectors. J Virol (1989) 2.86
Structural studies of avian myeloblastosis virus: comparison of polypeptides in virion and core component by dodecyl sulfate-polyacrylamide gel electrophoresis. J Virol (1974) 2.79
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51
Translational control of cytomegalovirus gene expression is mediated by upstream AUG codons. J Virol (1988) 2.35
Sequence requirements for activation of the HIV-1 LTR by human cytomegalovirus. Virology (1991) 1.99
A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res Hum Retroviruses (1988) 1.80
Transcellular transactivation by the human immunodeficiency virus type 1 tat protein. J Virol (1991) 1.57
High specific infectivity avian RNA tumor viruses. Virology (1974) 1.29
Rapid virus subunit visualization by direct sedimentation of samples on electron microscope grids. J Virol Methods (1987) 1.17
HIV-1 indicator cell lines. AIDS (1991) 1.13
Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol (1994) 6.60
Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J (1992) 6.05
Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology (1991) 5.54
Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature (1989) 5.12
Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell (1984) 4.29
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol (1995) 4.19
HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med (1998) 3.61
Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology (1997) 3.21
Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol (1990) 3.14
Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol (1996) 2.86
Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J (1996) 2.84
HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev (1998) 2.82
The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J Virol (1989) 2.46
VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J (1989) 2.45
HIV-1 infection requires a functional integrase NLS. Mol Cell (2001) 2.26
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
HIV-1 sequence variation: drift, shift, and attenuation. Cell (2001) 2.10
Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol Cell Biol (1986) 2.08
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis (1999) 2.07
Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding. J Virol (1989) 1.97
Instability of large direct repeats in retrovirus vectors. J Virol (1987) 1.78
High-frequency deletion in recovered retrovirus vectors containing exogenous DNA with promoters. J Virol (1984) 1.73
Vpx association with mature core structures of HIV-2. Virology (1996) 1.69
AIDS vaccine development. Science (1998) 1.62
Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J Virol (1997) 1.60
Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions. J Virol (1993) 1.52
Gene acquisition in HIV and SIV. Nature (1996) 1.51
An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol (2000) 1.44
Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J Virol (1999) 1.39
Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol (1999) 1.35
Spleen necrosis virus, an avian immunosuppressive retrovirus, shares a receptor with the type D simian retroviruses. J Virol (1992) 1.24
Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res (1986) 1.17
Small heat shock protein suppression of Vpr-induced cytoskeletal defects in budding yeast. Mol Cell Biol (1997) 1.09
Functional exchange of an oncoretrovirus and a lentivirus matrix protein. J Virol (1994) 1.07
Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect. Virology (1996) 1.03
Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden. Adv Exp Med Biol (1995) 0.95
Cleavage and cross-linking of proteins with osmium (VII) reagents. J Histochem Cytochem (1982) 0.87
Direct detection of infectious HIV-1 in blood using a centrifugation-indicator cell assay. J Virol Methods (2000) 0.86
From curse to cure: HIV for gene therapy? Nat Biotechnol (1996) 0.81
Learning from lentiviruses. Nat Genet (2000) 0.77
Insertion of genes into retrovirus genomes and of retrovirus DNA into cell genomes. Prog Med Virol (1985) 0.76
A competition model for viral inhibition of host cell proliferation. Math Biosci (2000) 0.75
RNA tumor virus update. Cancer Cells (1991) 0.75
Functional mapping of the rev-responsive element of human immunodeficiency virus type 2 (HIV-2): influence of HIV-2 envelope-encoding sequences on HIV-1 gp120 expression in the presence or absence of Rev. J Gen Virol (1992) 0.75